The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade has launched with more on the horizon (e.g., ND-0612, AP-CD/LD), two new rescue therapies for “off” periods will be available within the next three years (i.e., CVT-301 and APL-130277), and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Nuplazid, and Gocovri) or are in late-phase development (e.g., OS-320, HP-3000). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales in the PD market. However, given the cost-sensitivity of PD patients and widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.
QUESTIONS ANSWERED :
- What will be the impact of anticipated levodopa reformulations? Will they experience rapid uptake and alter the PD treatment paradigm, or will access hurdles and/or physician resistance limit use?
- What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?
- How will neurologists differentiate among current and next-generation levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which therapies will enjoy the greatest clinical and commercial success in the face of generics competition in the PD market?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.